CEL SCI CORP — Investor Relations & Filings
CEL-SCI Corporation is a clinical-stage biotechnology company engaged in the research and development of immunotherapies for cancer, autoimmune, and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a neoadjuvant treatment designed to stimulate a patient's immune system to fight cancer before standard treatments like surgery, radiation, and chemotherapy are administered. The company has completed a global pivotal Phase III clinical trial for Multikine in patients with advanced primary, previously untreated squamous cell carcinoma of the head and neck. The study demonstrated a significant 5-year overall survival benefit in a specific patient subgroup. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) technology platform for potential treatments of autoimmune and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| FORM 10-Q | 2026-05-15 | English | |
| FORM 8-K | 2026-05-14 | English | |
| 8-K - CEL SCI CORP (0000725363) (Filer) | 2026-05-13 | English | |
| 424B4 | 2026-05-13 | English | |
| Regulatory Filings 2026 | 2026-05-12 | English | |
| S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 46362719 | FORM 10-Q | 2026-05-15 | English | ||
| 46274090 | FORM 8-K | 2026-05-14 | English | ||
| 45766521 | 8-K - CEL SCI CORP (0000725363) (Filer) | 2026-05-13 | English | ||
| 46081758 | 424B4 | 2026-05-13 | English | ||
| 46081745 | Regulatory Filings 2026 | 2026-05-12 | English | ||
| 39639190 | S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | ||
| 46081761 | DEL AM | 2026-04-24 | English | ||
| 34662842 | S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English | ||
| 32880286 | 10-Q - CEL SCI CORP (0000725363) (Filer) | 2026-02-17 | English | ||
| 18269065 | 4 Filing | 2026-01-26 | English | ||
| 18269090 | 4 Filing | 2026-01-05 | English | ||
| 18269058 | 4 Filing | 2026-01-05 | English | ||
| 18269037 | 4 Filing | 2026-01-05 | English | ||
|
2025
2 filings
| |||||
| 18269100 | 10-K Filing | 2025-12-29 | English | ||
| 9417629 | PRIMARY DOCUMENT | 2025-12-05 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Sirnaomics Ltd.
Clinical-stage RNA therapeutics company, first to achieve p…
|
2257 | KY | Professional, scientific and te… |
|
Skye Bioscience, Inc.
Clinical-stage biotech developing treatments for obesity an…
|
SKYE | US | Professional, scientific and te… |
|
SLSBio(Specialty Lab Solution Bio) Co., Ltd
Offers lab services and manufactures diagnostics for the ph…
|
246250 | KR | Professional, scientific and te… |
|
SMO ClinPlus CO., LTD.
Provides clinical trial site management, CRC services, and …
|
301257 | CN | Professional, scientific and te… |
|
Soiken Holdings Inc.
Commercializes medical research via biomarker tech, clinica…
|
2385 | JP | Professional, scientific and te… |
|
Solid Biosciences Inc.
Develops gene therapies for rare neuromuscular and cardiac …
|
SLDB | US | Professional, scientific and te… |
|
Sona Nanotech Inc.
Develops and supplies proprietary gold nanorod technology f…
|
SONA | CA | Professional, scientific and te… |
|
SPARC TECHNOLOGIES LIMITED
Develops graphene technologies, green hydrogen, and sodium-…
|
SPN | AU | Professional, scientific and te… |
|
SpectraCure
Develops a minimally invasive treatment system for internal…
|
SPEC | SE | Professional, scientific and te… |
|
Sprint Bioscience
Develops and out-licenses preclinical oncology drug candida…
|
SPRINT | SE | Professional, scientific and te… |
CEL SCI CORP via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34401/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34401 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34401 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34401 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34401}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CEL SCI CORP (id: 34401)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.